PROWL › Markets explained › Tech

Skin cancer vaccine BLA submitted by...?

This event asks whether Moderna and Merck, or the FDA, will officially announce that a Biologics License Application (BLA) for intismeran autogene (also called mRNA-4157 or V940, the individualized skin cancer vaccine) has been submitted to the FDA. It also resolves Yes if the FDA has accepted such an application for review, or has approved the product, by the deadline. The key point is that plans and expected timing do not count. The submission must already have happened when the statement is made.

Leading right now: June 30, 2027? 80%, March 31, 2027 72%.

MarketChance of yesDeadline
Skin cancer vaccine BLA submitted by June 30, 2027?80.5%Jul 1, 2027, 3:59 UTC
Skin cancer vaccine BLA submitted by March 31, 2027?72.5%Apr 1, 2027, 3:59 UTC

Odds read from Polymarket at 22:18 UTC on Nov 21, 2026. $159K traded so far, $516 in the last 24 hours.

How this market resolves

Yes: Yes if, by the deadline, Moderna, Merck, the FDA, or their authorized representatives officially announce that a BLA for intismeran autogene has been submitted to the FDA, or that the FDA has accepted one for review. Yes also if the FDA approves the product by the deadline, even if no submission was announced separately. An original BLA or a resubmission after FDA action qualifies, for any indication.

No: No if none of these things has happened by the deadline. That means no announced BLA submission, no announced FDA acceptance for review, and no FDA approval. Statements of intent, plans, guidance, or expected filing timing do not make it Yes.

When it really ends

June 30, 2027, 11:59 PM ET for the June market. On that date New York is on daylight time (UTC-4), so this is 2027-07-01 03:59 UTC. The data's endDate matches this. The March market's rules text was not provided. Its title and endDate point to March 31, 2027, 11:59 PM ET, which is 2027-04-01 03:59 UTC. This assumes the same rules apply with only the date changed.

What counts

  • An official announcement from Moderna, Merck, or the FDA that a BLA has been submitted
  • An official announcement that the FDA has accepted a BLA for review
  • FDA approval of intismeran autogene by the deadline, even with no separate submission announcement
  • A resubmission of a BLA after FDA action
  • A BLA for any indication, not only the one studied in INTerpath-001
  • The product under any later brand or nonproprietary name, or a renamed or modified version the companies or FDA identify as the same program

What does not count

  • Statements of intent, plans, guidance, or expected timing for a filing
  • Trial results alone, including positive Phase 3 INTerpath-001 data, without a submission
  • Applications to regulators other than the FDA, or applications that are not BLAs
  • Announcements from parties who are not the company, the FDA, or their authorized representatives (credible-reporting consensus may be used, but only for a submission that has actually occurred)
  • Other Moderna or Merck products or unrelated cancer vaccines

Fine print people miss

What moves the price

Put a bot on this market

A PROWL bot reads the news around the clock, judges each post against these exact rules, and trades inside the limits you set. It starts in paper mode.

Questions people ask

What is intismeran autogene?

It is the individualized neoantigen therapy developed by Moderna and Merck, also known as mRNA-4157 or V940. It is tested in the Phase 3 INTerpath-001 trial (NCT05933577). The rules treat any later brand name or renamed version of the same program as the same product.

Does a BLA have to be submitted for this market to resolve Yes?

No. An official announcement of FDA acceptance for review also counts. So does FDA approval by the deadline, even if no submission was separately announced.

Does a company saying it plans to file count?

No. The submission must already have occurred when the statement is made. Statements of intent, plans, guidance, or expected timing do not qualify.

What is the deadline for the June market?

It is June 30, 2027 at 11:59 PM ET, which is 2027-07-01 03:59 UTC. The rules text governs, and here it agrees with the data's end date.

Does a filing for a different indication count?

Yes. The rules say the application may cover any indication. It must be a BLA seeking FDA licensure of intismeran autogene.

Who can make a qualifying announcement?

The company submitting the BLA, the FDA, or their authorized representatives. A consensus of credible reporting may also be used to resolve the market.

More Tech markets explained

Which company has best AI model end of 2026?$4.4M tradedTesla and SpaceX merger officially announced by...?$1.8M tradedWhich company has the best AI model end of November?$1.7M tradedJensen Huang divorce by...?$1.1M traded#1 Searched Person on Google 2026?$617K tradedFourth Jensen Huang affair reported by...?$398K tradedOpenAI announces it has achieved AGI before 2027?$382K traded#1 Searched Movie on Google 2026?$327K traded

Written from the market's own rules text on Nov 17, 2026. If the rules on Polymarket differ from this page, the rules on Polymarket govern.